Breast Cancer | Specialty

Dr. Yardley on Emerging Agents in HER2-Positive Breast Cancer

September 15th 2016

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses some of the emerging agents in HER2-positive breast cancer.

Biology of Triple-Negative Breast Cancer Crucial for Most Effective Treatment

September 15th 2016

It is important to achieve a complete and thorough understanding of triple-negative breast cancer in order to most effectively treat patients.

Dr. Cynthia Ma on Immunotherapy in TNBC

September 15th 2016

Dr. O'Shaughnessy on Precision Medicine in Triple Negative Breast Cancer

September 14th 2016

Joyce O'Shaughnessy, MD, co-chair, breast cancer research, chair breast cancer at Baylor University Medical Center, discusses precision medicine in triple negative breast cancer.

Dr. White on Omitting Radiation in Breast Cancer

September 13th 2016

Julia White, MD, professor of Radiation Oncology, Ohio State University Comprehensive Cancer Center, discusses the omission of radiation therapy for patients with breast cancer.

Dr. Mamounas on Adverse Events With Mastectomy in Breast Cancer

September 8th 2016

Eleftherios P. Mamounas, MD, surgical oncologist, UF Health Cancer Center - Orlando Health, discusses the common adverse events associated with mastectomy and breast conserving surgery for patients with breast cancer, as well as how oncologists can best manage these toxicities.

Obesity an Increasing Incidence in Breast Cancer, CRC Survivors

September 3rd 2016

Obesity is more prevalent in cancer survivors, specifically in those with a history of breast or colorectal cancer, compared with those without any history of disease.

Dr. Sunil Verma on Treatment for Early HER2+ Breast Cancer

September 2nd 2016

Dr. Kathy S. Albain on Breast Cancer Risk After 5 Years of Tamoxifen

September 1st 2016

Dr. White on Relationship Between Multigene Assays and RT in Breast Cancer

September 1st 2016

Julia White, MD, professor of Radiation Oncology, Ohio State University Comprehensive Cancer Center, discusses the relationship between multigene assays and radiation therapy in patients with breast cancer.

Dr. O'Connor on Ongoing Breast Cancer Research

August 30th 2016

Kathleen L. O'Connor, MD, professor, associate director of Cancer Education, Department of Molecular and Cellular Biochemistry, University of Kentucky Markey Cancer Center, discusses the ongoing research in the field of breast cancer.

Dr. Chandarlapaty on Role of the PI3K Pathway in Breast Cancer

August 29th 2016

Sarat Chandarlapaty, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of the PI3k pathway in patients with metastatic breast cancer.

Study Confirms MammaPrint's Accuracy in Assessing Treatment for Early Breast Cancer

August 26th 2016

Approximately 46% of patients with breast cancer at high risk for recurrence but low genomic risk with the 70-gene breast cancer recurrence assay (MammaPrint) might not require adjuvant chemotherapy.

Dr. Robson on Breast Cancer Risk Management

August 26th 2016

Dr. Hope Rugo on Trastuzumab Biosimilar in HER2-Positive Breast Cancer

August 24th 2016

EMA Initiates Official Regulatory Review of Neratinib in HER2+ Breast Cancer

August 23rd 2016

The European Medicines Agency has validated the marketing authorization application for neratinib as a potential extended adjuvant therapy for patients with HER2-positive early stage breast cancer following 12 months of trastuzumab.

Dr. Hudis on Combating Obesity in Breast Cancer

August 18th 2016

Clifford A. Hudis, MD, CEO, ASCO, discusses how oncologists should be helping patients with breast cancer overcome obesity.

Dr. Joyce O'Shaughnessy on Promising Agents in Triple-Negative Breast Cancer

August 17th 2016

Joyce O'Shaughnessy, MD, co-chair, breast cancer research, chair breast cancer at Baylor-Sammons Cancer Center, discusses what’s on the horizon in triple-negative breast cancer (TNBC). Checkpoint inhibitors, such as an anti-PD-1 agents, show a lot of promise in TNBC, said O’Shaughnessy. There are several studies investigating the use of checkpoint inhibitors with platinum agents and the preliminary data looks very good, she said.

Dr. Hurvitz on Steps to Take With HER2-Positive Breast Cancer Research

August 17th 2016

Sara Hurvitz, MD, medical oncologist, General Internal Medicine, Hematology and Oncology at UCLA, discusses steps needed to take in the field of HER2-positive breast cancer from a research perspective.

ASCO Recommends Standard Lumpectomy Margin Width for DCIS

August 15th 2016

A 2-mm margin should be the standard for patients with ductal carcinoma in situ undergoing breast conserving surgery with whole breast irradiation.